PAVM (PAVmed) 5-Year EBITDA Growth Rate: 0.00% (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

PAVM PAVmed Inc PAVM
32 GF Score
Price $4.92
GF Value $1.21
Valuation Significantly Overvalued
! 5 Warning Signs
View Full Analysis

What is PAVmed 5-Year EBITDA Growth Rate?

PAVmed PAVM -7.17% 32 5-Year EBITDA Growth Rate is 0.00% as of Jun. 2026. GuruFocus rates PAVM with a GF Score™ of 32/100 and a GF Value™ of $1.21 (Significantly Overvalued). The stock has 5 warning signs investors should review.

PAVmed's EBITDA per Share for the three months ended in Jun. 2026 was $-1.05.

During the past 12 months, PAVmed's average EBITDA Per Share Growth Rate was -137.80% per year. During the past 3 years, the average EBITDA Per Share Growth Rate was 80.90% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

During the past 12 years, the highest 3-Year average EBITDA Per Share Growth Rate of PAVmed was 80.90% per year. The lowest was -74.60% per year. And the median was -5.20% per year.

PAVmed  (NAS:PAVM) 5-Year EBITDA Growth Rate Explanation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

5-Year EBITDA Growth Rate gives an overview of the company's growth in operating profitability and is an important factor used in calculating Peter Lynch Fair Value.

PAVmed 5-Year EBITDA Growth Rate Related Terms

PAVM vs BDMD, NSPR, TELA: 5-Year EBITDA Growth Rate Comparison

For the Medical Devices subindustry, PAVmed's 5-Year EBITDA Growth Rate, along with its competitors' market caps and 5-Year EBITDA Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

PAVmed 5-Year EBITDA Growth Rate vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, PAVmed's 5-Year EBITDA Growth Rate distribution charts can be found below:

* The bar in red indicates where PAVmed's 5-Year EBITDA Growth Rate falls into.


PAVM
32GF Score
PAVmed Inc PAVM
5-Year EBITDA Growth Rate is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

PAVmed 5-Year EBITDA Growth Rate Calculation

This is the 5-year average growth rate of EBITDA per Share. The growth rate is calculated with least square regression.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

What does a 5-Year EBITDA Growth Rate of 0.00% mean?
PAVmed (PAVM) has a 5-Year EBITDA Growth Rate of 0.00% as of Jun. 2026. 5-Year EBITDA Growth Rate is the 5-year average growth rate of EBITDA per share. View historical data for PAVmed and its competitors.
Is PAVmed's 5-Year EBITDA Growth Rate too high?
PAVmed's current 5-Year EBITDA Growth Rate is 0.00%. Overall, PAVmed has a GF Score™ of 32/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does PAVmed's 5-Year EBITDA Growth Rate compare to BDMD and NSPR?
PAVmed's 5-Year EBITDA Growth Rate of 0.00% can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year EBITDA Growth Rate for a Medical Devices & Instruments company?
A good 5-Year EBITDA Growth Rate depends on the Medical Devices & Instruments industry context. However, 5-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year EBITDA Growth Rate mean?
A high 5-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 5-Year EBITDA Growth Rate is the 5-year average growth rate of EBITDA per share. View historical data for PAVmed and its competitors. PAVmed's current 5-Year EBITDA Growth Rate is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PAVmed stock overvalued right now?
Based on GuruFocus' analysis, PAVmed (PAVM) is currently considered Significantly Overvalued. The stock's GF Value™ is $1.21, compared to a current price of $4.92 — trading 306.6% above its estimated fair value. The current 5-Year EBITDA Growth Rate is 0.00%. PAVmed's overall GF Score™ is 32/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year EBITDA Growth Rate calculated?
5-Year EBITDA Growth Rate is calculated from a company's financial statements. For PAVmed (PAVM), the current 5-Year EBITDA Growth Rate is 0.00% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is PAVmed (PAVM) Overvalued in 2026?

Based on GuruFocus' analysis, PAVmed stock appears to be overvalued. The current stock price of $4.92 is trading 306.6% above its estimated GF Value™ of $1.21. GuruFocus considers PAVmed to be Significantly Overvalued.

Key valuation signals for PAVM:

  • 5-Year EBITDA Growth Rate: 0.00%
  • GF Value™: $1.21 vs. price of $4.92 (306.6% above fair value)
  • GF Score™: 32/100 with 5 warning signs

No single metric tells the full story. See the PAVM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

PAVmed Business Description

Other Exchanges 1P5:Germany
Address 360 Madison Avenue, 25th Floor, New York, NY, USA, 10017
PAVmed Inc is a multi-product, commercial-stage medical technology company organized to advance a broad pipeline of medical technologies from concept to commercialization. The company operates in a single segment as a medical technology company, with the following lines of business: Diagnostics, Medical Devices, and Digital Health. Its products are EsoGuard, EsoCheck, and the Veris Cancer Care Platform.
32GF Score

Get the complete analysis for PAVM

5-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$4.92
Price
$1.21
GF Value